Taysha Gene Therapies, Inc. (TSHA) stock
TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.00−0.06 (-1.48%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
Taysha Gene Therapies profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Taysha Gene Therapies's profit margin for the twelve months ending Jun 30, 2026 was -2728.0%. For fiscal 2025 it was -1115.3%, against -1071.6% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1115.3% | −43.6 |
| FY2024 | Dec 31, 2024 | -1071.6% | −349.6 |
| FY2023 | Dec 31, 2023 | -722.1% | +5913.2 |
| FY2022 | Dec 31, 2022 | -6635.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -507.8% | +919.8 |
| Q2 FY2025 | Jun 30, 2025 | -1353.6% | +528.4 |
| Q1 FY2025 | Mar 31, 2025 | -935.2% | −229.8 |
| Q4 FY2024 | Dec 31, 2024 | -929.0% | −2253.7 |
| Q3 FY2024 | Sep 30, 2024 | -1427.5% | +1039.6 |
| Q2 FY2024 | Jun 30, 2024 | -1882.0% | −855.0 |
| Q1 FY2024 | Mar 31, 2024 | -705.4% | −330.9 |
| Q4 FY2023 | Dec 31, 2023 | 1324.7% | – |
| Q3 FY2023 | Sep 30, 2023 | -2467.1% | – |
| Q2 FY2023 | Jun 30, 2023 | -1027.1% | – |
| Q1 FY2023 | Mar 31, 2023 | -374.5% | – |
See a number that looks wrong?